8 recruiting, 6 completed, 3 terminated, 3 withdrawn. 21 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Recruiting 8, Completed 6, Terminated 3, Withdrawn 3, Not yet recruiting 1 |
| Phase 2 | 7 | Recruiting 4, Completed 1, Terminated 1, Withdrawn 1 |
Follow Pheochromocytoma: new trials by email Literature Review of Pheochromocytoma trials Research Report on Pheochromocytoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 211At-MABG in Adults With Advanced Neuroendocrine Cancers 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated - Pheochromocytoma, Paraganglioma | Phase 1 | Not yet recruiting | University of Pennsylvania | 16 | 2026-12-01 | 2026-10-07 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET - Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-02-07 | 2026-10-16 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors ADCT-701 - Neuroendocrine Carcinomas, Neuroendocrine Tumors | Phase 1 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-06-17 | 2026-11-09 |
| Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors [203Pb]VMT-α-NET, [212Pb]VMT-α-NET - Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-09-27 | 2026-10-13 |
| HTL0039732 in Participants With Advanced Solid Tumours HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion - Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Cancer Research UK | 150 | 2023-08-02 | 2026-10-01 |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies DFF332, RAD001, PDR001 - Carcinoma, Renal Cell | Phase 1 | Terminated | Novartis Pharmaceuticals | 40 | 2021-11-30 | 2026-03-03 |
| Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents 177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT) - Neuroendocrine Tumors, Pheochromocytoma | Phase 1 / Phase 2 | Withdrawn | Sue O'Dorisio | 2020-08-04 | 2021-06-08 | |
| A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma EO2401, Nivolumab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 1 / Phase 2 | Terminated | Enterome | 70 | 2020-07-23 | 2026-01-30 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Vandetanib, 131I-mIBG - Phaeochromocytoma, Paraganglioma | Phase 1 | Withdrawn | University College, London | 2014-10-01 | 2015-12-21 | |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma | Phase 1 | Completed | University of Southern California | 19 | 2010-06-01 | 2016-06-13 |
| Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Ultratrace Iobenguane (MIBG) I 131 - Pheochromocytoma, Paraganglioma | Phase 1 / Phase 2 | Completed | Molecular Insight Pharmaceuticals, Inc. | 24 | 2007-04-01 | 2016-07-13 |
| ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Ultratrace iobenguane I 131 - Pheochromocytoma, Paraganglioma | Phase 1 | Completed | Molecular Insight Pharmaceuticals, Inc. | 24 | 2006-06-01 | 2011-10-12 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma | Phase 1 | Completed | Mayo Clinic | 96 | 2004-12-01 | 2024-08-21 |
| Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors 90Y-DOTA-tyr3-OCTREOTIDE - Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor | Phase 1 | Completed | O'Dorisio, M S | 27 | 2002-01-01 | 2016-06-21 |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum floxuridine, leucovorin calcium, oxaliplatin - Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 2000-04-01 | 2011-04-26 | |
| Diagnosis of Pheochromocytoma ([18F]-DOPA), ([18F]-6F-DA) - Pheochromocytoma, Endocrine Disease | Phase 1 | Recruiting | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 3000 | 2000-03-22 | 2026-10-08 |
Showing 20 of 21. Sign in to see all of them.
Paraganglioma (13) · Neuroendocrine Tumors (10) · Carcinoma, Islet Cell (5) · Carcinoma, Medullary (5) · Insulinoma (5) · Carcinoma, Merkel Cell (4) · Carcinoma, Renal Cell (4) · Gastrinoma (4) · Glucagonoma (4) · Neuroblastoma (4) · Somatostatinoma (4) · Adenoma, Islet Cell (3) · Adrenocortical Carcinoma (3) · Esthesioneuroblastoma, Olfactory (3)
Neoplasms by Histologic Type (21) · Neoplasms, Germ Cell and Embryonal (21) · Neoplasms, Nerve Tissue (21) · Neuroectodermal Tumors (21) · Neoplasms (18) · Neoplasms, Glandular and Epithelial (15) · Neoplasms by Site (14) · Carcinoma (13) · Adenocarcinoma (12) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11) · Neuroendocrine Tumors (11) · Digestive System Diseases (8) · Digestive System Neoplasms (8) · Pancreatic Diseases (8)
3-Iodobenzylguanidine (2) · Everolimus (2) · gallium Ga 68 dotatate (2) · lutetium Lu 177 dotatate (2) · 6-fluorodopamine (1) · Biopsy (1) · Capecitabine (1) · Cyclophosphamide (1) · Floxuridine (1) · Fluorodeoxyglucose F18 (1) · High-Energy Shock Waves (1) · Interleukin-13 (1) · Iodine-131 (1) · Leucovorin (1) · Magnetic Resonance Spectroscopy (1)
National Cancer Institute (NCI) (3) · Molecular Insight Pharmaceuticals, Inc. (2) · Anusha Kalbasi (1) · Cancer Research UK (1) · Enterome (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Fundación de investigación HM (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · O'Dorisio, M S (1) · Perspective Therapeutics (1) · Sue O'Dorisio (1) · University College, London (1) · University of Pennsylvania (1)
United States (16) · Spain (3) · France (2) · Italy (2) · United Kingdom (2) · Czechia (1) · Denmark (1) · Germany (1) · Japan (1) · Netherlands (1) · Singapore (1) · Sweden (1)
Frank I Lin, M.D. (2) · M. Sue O'Dorisio, MD, PhD (2) · Agustin Garcia (1) · Allison Betof Warner, MD, PhD (1) · Antoni Ribas, MD, PhD (1) · Catherine M Gordon, M.D. (1) · Christina Thirlwell (1) · Jaydira Del Rivero, M.D. (1) · Jean-Michel Paillarse (1) · John R. Murren, MD (1) · Jordan Berlin, M.D. (1) · Julian R. Molina, M.D., Ph.D. (1) · Leonard B. Saltz, MD (1) · Marta Osuna Marco, PhD (1)
PMID 20847174, PMID 29099942, PMID 29534198, PMID 31057686, PMID 31231443, PMID 34431366, PMID 39416174, PMID 40595495, PMID 42558019
R01CA300202 (1)